Mylan confident on biosim Herceptin in India despite Roche tactics
This article was originally published in Scrip
Executive Summary
Mylan has said that it and partner Biocon were given no prior warning of the recent legal action by Roche when the Swiss company sought to block their biosimilar versions of Herceptin (trastuzumab) in India.